Skip to content

Randomised controlled trial (RCT) of home HIV testing to increase HIV testing frequency

A randomised controlled trial of home HIV testing to increase HIV testing frequency among gay men in the home testing arm compared to standard clinic-based HIV testing

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613001236785
Acronym
FORTH: Frequency of Oral Rapid Testing at Home
Enrollment
362
Registered
2013-11-12
Start date
2013-12-02
Completion date
2015-02-05
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This randomised controlled trial (RCT) aims to assess the effectiveness, acceptability and feasibility of home HIV testing among gay men in Australia. Approximately 350 high risk gay men (including 50 men who report their last HIV test was more than 24 months ago) will be recruited from clinics and community-based sites and randomised 1:1 to one of the two study arms: home HIV testing arm (intervention); or clinic HIV testing arm (control). At enrolment, all study procedures will be explained to the participants and they will be required to sign a written consent form which will cover all data collection activities of the trial. The OraQuick In-Home HIV Test will be used for home HIV testing in this study. It is a rapid self-administered over-the-counter (OTC) test which is used with an oral fluid specimen and provides a result 20 minutes after specimen collection. The test is developed by OraSure Technologies Inc., (Bethlehem, Pennsylvania, United States) and is approved for home use in the United States (US) by the Food and Drug Administration (FDA). It is not yet approved by the Therapeutic Goods Administration (TGA) of Australia, but can be imported to Australia for personal use and research purposes. This is a wait-list control RCT, with each participant followed-up for 24 months after enrolment. After initial 12 months, participants in the clinic HIV testing arm will switch to home HIV testing arm, so that all the participants will have access to home HIV testing in the last 12 months. At enrolment, men in the home testing arm will receive four OraQuick home tests with written and video instructions. Further home tests will be available on request, with a maximum of 12 kits per participant per year. Ongoing support via a 24 hour phone line will be available to men in the home HIV testing arm throughout the study. Men in both arms will have access to routine HIV testing and care at their preferred clinic. Demographic, sexual behaviour and HIV/STI testing information will be collected from participants through a self-administered questionnaire at enrolment. Every 3 months, brief information on HIV/STI tests and the results will be collected through an online self-administered questionnaire. In addition, HIV/STI test results will be collected from clinics attended by the participants during the study period. At 12 and 24 months, these questionnaires will include additional questions to collect information on acceptability of clinic and home HIV testing and confidence on the performance of home HIV test. At the end of study, selected participants will be invited to participate in in-depth interviews to obtain detailed information about their home test experience and influence on sexual behaviour.

Interventions

Home HIV testing - Participants randomised to the intervention arm will have access to home HIV test kits in addition to routine clinic-based HIV and other sexually transmitted infection (STI) testing. They will receive four home HIV test kits with written and video instructions at enrolment. They will be able to request additional home test kits if required during 24 months of follow-up for up-to 12 kits per year. No training will be provided to participants for home HIV testing at enrolment.

Home HIV testing - Participants randomised to the intervention arm will have access to home HIV test kits in addition to routine clinic-based HIV and other sexually transmitted infection (STI) testing. They will receive four home HIV test kits with written and video instructions at enrolment. They will be able to request additional home test kits if required during 24 months of follow-up for up-to 12 kits per year. No training will be provided to participants for home HIV testing at enrolment. The OraQuick In-Home HIV Test (OraSure Technologies Inc., Bethlehem, Pennsylvania, United States) will be used for home HIV testing in this study. It is a rapid self-administered HIV antibody test which is used with an oral fluid specimen and provides a result 20 minutes after specimen collection. The test is approved for home use in the United States (US) by the Food and Drug Administration (FDA). It is not yet approved by the Therapeutic Goods Administration (TGA) of Australia, but can be imported to Australia for personal use and research purposes. Due to wait-list control design, participants randomised to the control arm (standard clinic-based testing) will also have access to home HIV test kits for one year after initial 12 months of follow-up.

Sponsors

University of New South Wales
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Other
Primary purpose
Diagnosis
Masking
Blinded (masking used) (Investigator)

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Men identifying themselves as gay (men who have sex with men), AND Aged 18 years or above, AND Plan to stay in Australia for next 2 years, AND Any unprotected anal intercourse (UAI) in the last 3 months, OR >5 partners in the last 3 months

Exclusion criteria

Men known to be HIV-positive or diagnosed as HIV positive at the current clinic visit, OR Men commencing HIV post-exposure prophylaxis, OR Men who cannot speak and/or read English, OR Men who cannot provide their own consent, OR Unwilling or unable to comply with all the requirements of the study

Outcome results

None listed

Source: ANZCTR · Data processed: Mar 14, 2026